At a Glance
- Company: Ascendis Pharma A/S (Nasdaq: ASND)
- Location: Copenhagen, Denmark
- Headline figures: Once‑weekly CNP prodrug for children ≥2 years
- Focus area: Achondroplasia (most common dwarfism)
- Next steps: US launch early Q2 2026; EU decision Q4 2026
What happened?
The FDA has granted accelerated approval to Yuviwel (navepegritide), Ascendis Pharma’s once‑weekly injectable treatment to increase linear growth in children aged two years and older with achondroplasia and open growth plates. The decision, announced on 27 February 2026, is based on phase 2b data showing significant improvements in annualised growth velocity versus placebo and positions Yuviwel directly against BioMarin’s once‑daily Voxzogo in the dwarfism market.
Why does it matter?
Achondroplasia is the most common form of dwarfism, affecting roughly 1 in 15,000–40,000 births, and is caused by gain‑of‑function mutations in FGFR3 that blunt bone growth. Yuviwel delivers sustained exposure to C‑type natriuretic peptide (CNP), counteracting FGFR3 signalling with a more convenient weekly regimen that could be particularly attractive for children and families currently facing daily injections with Voxzogo. The approval also came with a rare paediatric disease priority review voucher, a valuable asset Ascendis can use or sell, often for 100–200 million USD.
Who’s behind it?
Ascendis, a Danish biotech specialising in long‑acting “TransCon” prodrugs, already markets Skytrofa for paediatric growth hormone deficiency and Yorvipath for hypoparathyroidism. CEO Jan Mikkelsen said the company worked closely with dwarfism advocacy groups to prioritise outcomes that matter to patients and families and expects its three approved TransCon products—including Yuviwel—to collectively exceed €5 billion in annual sales by 2030.
How was it achieved?
Yuviwel is a TransCon CNP prodrug that provides continuous systemic exposure to CNP over a weekly dosing interval, designed to rebalance overactive FGFR3 signalling in growth plates. The FDA’s accelerated approval was supported primarily by the 84‑patient phase 2b ApproaCH trial and additional controlled and extension studies, which showed clinically meaningful gains in annualised growth velocity versus placebo with an acceptable safety profile. Continued approval is contingent on confirmatory trials, including longer‑term outcome studies already under way.
What’s next?
Ascendis plans to make Yuviwel available in the US early in the second quarter of 2026 and to support access through its Ascendis Signature Access Program, offering navigation and financial assistance for eligible patients. The company is running the reACHin trial in children under two years old and planning adult studies, aiming to broaden Yuviwel’s label and further entrench it against Voxzogo as payers and clinicians weigh daily versus weekly CNP‑based therapy.